Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Systematic review of MS proteomics/metabolomics in multiple myeloma cohorts
New Blood Test Spots Myeloma Return Months Earlier
This systematic review synthesizes evidence from 19 studies involving 1,077 screened records regarding quantitative mass spectrometry-based …
This new test could give patients and doctors a critical head start in fighting a return of multiple myeloma.
Case Report Describes Non-Secretory Multiple Myeloma With Eosinophilia in a 56-Year-Old Man
Back Pain and High White Cells: A Hidden Cancer Case
This case report details a 56-year-old man presenting with multiple myeloma and eosinophilia.
This case shows how a rare blood cancer can hide behind common symptoms, making early diagnosis difficult but crucial.
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma.
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen.
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …